News

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process.

Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and other commodities in highly energetically favorable (high yield, high purity) production. Allozymes is optimizing key enzymes in the pathway to meet large-scale production specifications. The collaboration includes Allozymes’ cutting edge microfluidics-based protein engineering platform to achieve what was previously thought impossible: analyzing up to 20 million enzyme variants a day, delivering superior success rates, and dramatically reducing development timelines for novel enzymes.

“Optimizing enzymes for industrial-scale production requires precision, speed, and innovation, and our collaboration with Bonumose exemplifies this,” said Akbar Vahidi, Chief Technology Officer of Allozymes. “By leveraging our microfluidics-based protein engineering platform, we have been able to rapidly enhance key enzymes, significantly improving the process efficiency and scalability. The early results are promising, and we are confident that this partnership will unlock new possibilities in sustainable and cost-effective ingredient production.”

Dr. Daniel Wichelecki, Bonumose’s Chief Scientific Officer and Co-Founder, states, “Our mission is to produce healthy food and supplement ingredients in a low-cost, scalable production process. Our development collaborator Allozymes has shown promising results in the initial phases of our collaboration. We are on track and confident to meet our developmental objectives.”

The companies are pleased with the important milestone in both companies’ agenda of leveraging the use of enzymes to accelerate timelines and meet ambitious targets for producing beneficial ingredients to meet global needs for healthy food, dietary supplements, and other important categories.

“Our goal is to drive the future of sustainable food ingredient production through enzyme innovation,” said Akbar Vahidi. “Our collaboration with Bonumose is a critical part of this mission and we aim to demonstrate a successful model on how Allozymes enables innovation in the food ingredient market. With our unique platform, we are confident that we’ll continue to reduce development timelines and enhance performance, setting a new benchmark in the industry.”

 

Read more here.

Recent News

09/03/2026

Seppic announces the appointment of Virginie Cavalli as Chief Executive Officer

A subsidiary of Air Liquide Healthcare, Seppic designs, manufactures, and distributes a wide range of specialty ingredients used in cosmetics, nutraceuticals, pharmaceuticals, veterinary products, and industrial applications. Nearly 900 employees support customers in 100 countries through the company’s subsidiaries and distributor network. With a degree from EMLyon school in business and financial strategy, Virginie Cavalli

09/01/2026

Andre Marshall to join National Science Foundation; Aurali Dade named Interim Vice President for Research, Innovation, and Economic Impact

Since joining George Mason in 2021, Marshall has played a pivotal role in advancing the university’s research enterprise and entrepreneurial ecosystem and strengthening the university’s reputation as a leading public R1 institution, including launching the Grand Challenge Initiative and empowering institute-driven initiatives like Nexus234 and the Virginia Climate Center. During Marshall’s tenure, George Mason expanded research activity and strategic partnerships,

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the